South Africa is set to become the first African country to manufacture a generic version of an injectable HIV-prevention drug known as cabotegravir.
The drug, which is administered as an injection every two months, is highly effective in preventing HIV infection. The South African government has recently announced an agreement with India-based Cipla to manufacture the drug locally, making it more affordable and accessible to people in need. This is a significant step forward in the fight against HIV/AIDS in the country, and it is hoped that other African countries will soon follow suit.